• 1. An artificial CO-releasing metalloprotein built by histidine-selective metallation?
  Inês S. Albuquerque,Hélia F. Jeremias,Miguel Chaves-Ferreira,Dijana Matak-Vinkovic,Omar Boutureira,Carlos C. Rom?o Chem. Commun., 2015,51, 3993-3996
• 2. An amphoteric reactivity of a mixed-valent bis(μ-oxo)dimanganese(iii,iv) complex acting as an electrophile and a nucleophile?
  Muniyandi Sankaralingam,So Hyun Jeon,Yong-Min Lee,Mi Sook Seo,Wonwoo Nam Dalton Trans., 2016,45, 376-383
• 3. An all-solid-state imprinted polymer-based potentiometric sensor for determination of bisphenol S?
  Rongning Liang,Tanji Yin,Ruiqing Yao,Wei Qin RSC Adv., 2016,6, 73308-73312
• 4. An atom efficient route to N-aryl and N-alkyl pyrrolines by transition metal catalysis?
  Supaporn Sawadjoon,Joseph S. M. Samec Org. Biomol. Chem., 2011,9, 2548-2554
• 5. An integrated microfluidic platform for sensitive and rapid detection of biological toxins?
  Robert J. Meagher,Anson V. Hatch,Ronald F. Renzi,Anup K. Singh Lab Chip, 2008,8, 2046-2053

Introduction to 6-ethyl-1,2,3,4-tetrahydroisoquinoline (CAS No. 404576-43-8)

6-ethyl-1,2,3,4-tetrahydroisoquinoline, identified by its Chemical Abstracts Service (CAS) number 404576-43-8, is a heterocyclic organic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal biology. This compound belongs to the tetrahydroisoquinoline (THIQ) class, a structural motif widely recognized for its biological activity and pharmacological relevance. The presence of an ethyl substituent at the 6-position of the isoquinoline core introduces unique electronic and steric properties, making it a promising scaffold for drug discovery and development.

The tetrahydroisoquinoline scaffold is inherently interesting due to its structural similarity to numerous bioactive natural products and pharmacologically relevant molecules. Compounds within this class have been extensively studied for their potential roles in modulating various biological pathways, including neurotransmitter systems, cardiovascular function, and cancer cell proliferation. The 6-ethyl-1,2,3,4-tetrahydroisoquinoline derivative represents a tailored modification of this scaffold, designed to explore novel pharmacological interactions while retaining the inherent advantages of the THIQ core.

Recent advancements in computational chemistry and molecular modeling have facilitated a deeper understanding of the interactions between 6-ethyl-1,2,3,4-tetrahydroisoquinoline and biological targets. These studies suggest that the ethyl group at the 6-position may enhance binding affinity to specific protein receptors by influencing both hydrophobic interactions and electronic distribution. Such insights are crucial for rational drug design and optimization efforts aimed at developing high-affinity ligands with improved pharmacokinetic profiles.

In the realm of medicinal chemistry, 6-ethyl-1,2,3,4-tetrahydroisoquinoline has been explored as a precursor for more complex derivatives. Functionalization strategies at other positions within the molecule have led to the synthesis of analogs with enhanced bioavailability or altered selectivity profiles. For instance, modifications at the 1-position or incorporation of additional aromatic rings have been investigated for their potential to modulate receptor binding affinities and metabolic stability.

The biological activity of tetrahydroisoquinoline derivatives is often linked to their ability to interact with monoamine transporters and receptors. Preliminary in vitro studies on 6-ethyl-1,2,3,4-tetrahydroisoquinoline have revealed promising interactions with serotonin (5-HT) transporters and dopamine receptors. These findings align with the broader interest in THIQ derivatives as potential therapeutic agents for neurological disorders such as depression and Parkinson??s disease. The ethyl substituent appears to fine-tune these interactions without significantly compromising binding affinity or selectivity.

Moreover, the synthesis of 6-ethyl-1,2,3,4-tetrahydroisoquinoline has been optimized using modern catalytic methods that enhance yield and purity while minimizing environmental impact. Transition-metal-catalyzed reactions have played a pivotal role in streamlining key synthetic steps, ensuring scalability for both research-scale preparations and potential industrial applications. These advancements underscore the growing importance of sustainable chemistry practices in pharmaceutical development.

The pharmacokinetic properties of 6-ethyl-1,2,3,4-tetrahydroisoquinoline are also under active investigation. Initial pharmacokinetic studies indicate moderate oral bioavailability coupled with a reasonable half-life in preclinical models. These characteristics make it an attractive candidate for further development into an oral therapeutic agent. However， additional studies are needed to fully characterize its metabolic pathways and potential drug-drug interaction liabilities.

Recent research has highlighted the role of tetrahydroisoquinoline derivatives in modulating inflammation and immune responses. Studies suggest that certain THIQ analogs can influence cytokine production and immune cell function through interactions with intracellular signaling pathways. The ethyl-substituted derivative may exhibit similar effects but with distinct potency or selectivity profiles. Further exploration of these mechanisms could open new avenues for therapeutic intervention in inflammatory diseases.

The structural diversity within the tetrahydroisoquinoline class allows for extensive derivatization while maintaining core pharmacophoric features. This flexibility has enabled chemists to design molecules with tailored properties for specific therapeutic applications. For example,6-ethyl-1,2,3,4-tetrahydroisoquinoline could serve as a lead compound for developing treatments targeting neurodegenerative disorders or chronic pain syndromes where modulation of neurotransmitter systems is key.

In conclusion,6-ethyl-1，2，3，4-tetrahydroisoquinoline (CAS No．404576—43—8) represents a compelling example of how structural modifications within a well-studied scaffold can yield novel bioactive compounds．The ethyl substituent at the 6-position introduces unique pharmacological properties that make this derivative attractive for further exploration．Advances in synthetic methodologies、computational modeling、and preclinical evaluation continue to enhance our understanding of its potential applications．As research progresses，this compound may emerge as a valuable tool in addressing unmet medical needs across multiple therapeutic areas．

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)